Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

BMJ : British Medical Journal
Munir PirmohamedAlasdair M Breckenridge

Abstract

To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital. Prospective observational study. Two large general hospitals in Merseyside, England. 18 820 patients aged > 16 years admitted over six months and assessed for cause of admission. Prevalence of admissions due to an ADR, length of stay, avoidability, and outcome. There were 1225 admissions related to an ADR, giving a prevalence of 6.5%, with the ADR directly leading to the admission in 80% of cases. The median bed stay was eight days, accounting for 4% of the hospital bed capacity. The projected annual cost of such admissions to the NHS is 466m pounds sterling (706m Euros, 847m dollars). The overall fatality was 0.15%. Most reactions were either definitely or possibly avoidable. Drugs most commonly implicated in causing these admissions included low dose aspirin, diuretics, warfarin, and non-steroidal anti-inflammatory drugs other than aspirin, the most common reaction being gastrointestinal bleeding. The burden of ADRs on the NHS is high, accounting for considerable morbidity, mortality, and extra costs. Although many of the implicated drugs have proved benefit, measures need to be put into place to redu...Continue Reading

Associated Clinical Trials

Apr 30, 2018·Professor Sir Munir Pirmohamed

References

Jul 1, 1986·Age and Ageing·S Leach, S S Roy
Mar 1, 1969·British Medical Journal·N Hurwitz, O L Wade
Mar 1, 1969·British Medical Journal·N Hurwitz
Mar 1, 1969·British Medical Journal·N Hurwitz
Apr 1, 1995·BMJ : British Medical Journal·J WeilP Wainwright
Oct 1, 1996·British Journal of Clinical Pharmacology·C C SmithD G Grahame-Smith
Jan 22, 1997·JAMA : the Journal of the American Medical Association·D C ClassenJ P Burke
Jan 22, 1997·JAMA : the Journal of the American Medical Association·D W BatesL L Leape
Apr 29, 1998·JAMA : the Journal of the American Medical Association·J LazarouP N Corey
Nov 10, 2000·Lancet·I R Edwards, J K Aronson
Jun 7, 2002·The New England Journal of Medicine·Jean-Michel GaspozLee Goldman
Jun 28, 2002·The Annals of Pharmacotherapy·Almut G WintersteinCharles Poole
Jun 17, 2003·PharmacoEconomics·Rosa Rodríguez-MonguióJoan Rovira

❮ Previous
Next ❯

Citations

Apr 24, 2008·Aging Clinical and Experimental Research·Elmo Jensen, Marianne Schroll
Oct 29, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·D Grandt
Apr 9, 2010·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·C Scheidt-NaveA Kuhlmey
Dec 21, 2013·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·E NowossadeckK Kraywinkel
Oct 15, 2009·Social Psychiatry and Psychiatric Epidemiology·Natasa GisevTimothy F Chen
Jun 4, 2011·Calcified Tissue International·René RizzoliCyrus Cooper
Apr 13, 2005·European Journal of Clinical Pharmacology·A P Jonville-BéraE Autret-Leca
Dec 31, 2005·European Journal of Clinical Pharmacology·Alberto PilottoUNKNOWN SOFIA Project Investigators
Jan 6, 2006·European Journal of Clinical Pharmacology·Aline Lins CamargoIsabela Heineck
Jun 11, 2005·European Journal of Clinical Pharmacology·I HachW Kirch
Sep 7, 2007·European Journal of Clinical Pharmacology·Priska VonbachStephan Krähenbühl
Jan 9, 2008·European Journal of Clinical Pharmacology·Shaojun ShiUlrich Klotz
Jan 4, 2008·European Journal of Clinical Pharmacology·I Ralph Edwards
Apr 4, 2008·European Journal of Clinical Pharmacology·Borja RuizCarmelo Aguirre
Oct 3, 2009·European Journal of Clinical Pharmacology·Monica BergqvistEva Andersén Karlsson
Jun 29, 2010·European Journal of Clinical Pharmacology·Guillermo GervasiniJuan Antonio Carrillo
Jan 22, 2011·European Journal of Clinical Pharmacology·Johanna Strandell, Stina Wahlin
Feb 15, 2011·European Journal of Clinical Pharmacology·Lina M HellströmTommy Eriksson
Mar 12, 2011·European Journal of Clinical Pharmacology·Marco EgbringGerd A Kullak-Ublick
Jun 28, 2011·European Journal of Clinical Pharmacology·Maria A P MartinsAntonio L P Ribeiro
Aug 16, 2011·European Journal of Clinical Pharmacology·Carmen C FranzStephan Krähenbühl
Dec 15, 2011·European Journal of Clinical Pharmacology·Asia N RashedAntje Neubert
Feb 22, 2012·European Journal of Clinical Pharmacology·Gunhild NyborgMette Brekke
Feb 22, 2012·European Journal of Clinical Pharmacology·Henrik LövborgStaffan Hägg
Feb 21, 2013·European Journal of Clinical Pharmacology·Sigrid NarumMarianne Kristiansen Kringen
May 10, 2013·European Journal of Clinical Pharmacology·Gunnar AlvánElisabeth Törnqvist
May 10, 2013·European Journal of Clinical Pharmacology·Nicholas Moore
Dec 29, 2010·Journal of Molecular Evolution·Tamara SchenekarSteven Weiss
Jun 21, 2005·Zeitschrift für Gerontologie und Geriatrie·M Vass, C Hendriksen
Jun 21, 2005·Zeitschrift für Gerontologie und Geriatrie·D GrandtW Häuser
Sep 29, 2005·Zeitschrift für Gerontologie und Geriatrie·M Vass, C Hendriksen
Aug 19, 2007·Zeitschrift für Gerontologie und Geriatrie·H BurkhardtR Gladisch
Feb 8, 2006·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Thomas RosemannJoachim Szecsenyi
Jul 20, 2010·Wiener medizinische Wochenschrift·Ronald OttoMarkus Gosch
Jul 20, 2010·Wiener medizinische Wochenschrift·Markus GoschUlrike Sommeregger
Nov 5, 2011·Journal of Genetic Counseling·Alice CallardKatherine Payne

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.